Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells

Bradley E Britigan, T. S. Lewis, M. Waldschmidt, M. L. McCormick, A. M. Krieg

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Unmethylated CpG dinucleotide motifs in bacterial DNA, as well as oligodeoxynucleotides (ODN) containing these motifs, are potent stimuli for many host immunological responses. These CpG motifs may enhance host responses to bacterial infection and are being examined as immune activators for therapeutic applications in cancer, allergy/asthma, and infectious diseases. However, little attention has been given to processes that down-modulate this response. The iron-binding protein lactoferrin is present at mucosal surfaces and at sites of infection. Since lactoferrin is known to bind DNA, we tested the hypothesis that lactoferrin will bind CpG-containing ODN and modulate their biological activity. Physiological concentrations of lactoferrin (regardless of iron content) rapidly bound CpG ODN. The related iron-binding protein transferrin lacked this capacity. ODN binding by lactoferrin did not require the presence of CpG motifs and was calcium independent. The process was inhibited by high salt, and the highly cationic N-terminal sequence of lactoferrin (lactoferricin B) was equivalent to lactoferrin in its ODN-binding ability, suggesting that ODN binding by lactoferrin occurs via chargecharge interaction. Heparin and bacterial LPS, known to bind to the lactoferricin component of lactoferrin, also inhibited ODN binding. Lactoferrin and lactoferricin B, but not transferrin, inhibited CpG ODN stimulation of CD86 expression in the human Ramos B cell line and decreased cellular uptake of ODN, a process required for CpG bioactivity. Lactoferrin binding of CpG-containing ODN may serve to modulate and terminate host response to these potent immunostimulatory molecules at mucosal surfaces and sites of bacterial infection.

Original languageEnglish (US)
Pages (from-to)2921-2928
Number of pages8
JournalJournal of Immunology
Volume167
Issue number5
DOIs
StatePublished - Sep 1 2001
Externally publishedYes

Fingerprint

Lactoferrin
Oligodeoxyribonucleotides
Oligonucleotides
B-Lymphocytes
Iron-Binding Proteins
Transferrin
Bacterial Infections
lactoferricin B
Bacterial DNA
Communicable Diseases
Heparin
Hypersensitivity
Asthma
Iron
Salts
Calcium

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells. / Britigan, Bradley E; Lewis, T. S.; Waldschmidt, M.; McCormick, M. L.; Krieg, A. M.

In: Journal of Immunology, Vol. 167, No. 5, 01.09.2001, p. 2921-2928.

Research output: Contribution to journalArticle

Britigan, Bradley E ; Lewis, T. S. ; Waldschmidt, M. ; McCormick, M. L. ; Krieg, A. M. / Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells. In: Journal of Immunology. 2001 ; Vol. 167, No. 5. pp. 2921-2928.
@article{1d76357eb973452990acb95c86ba0de6,
title = "Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells",
abstract = "Unmethylated CpG dinucleotide motifs in bacterial DNA, as well as oligodeoxynucleotides (ODN) containing these motifs, are potent stimuli for many host immunological responses. These CpG motifs may enhance host responses to bacterial infection and are being examined as immune activators for therapeutic applications in cancer, allergy/asthma, and infectious diseases. However, little attention has been given to processes that down-modulate this response. The iron-binding protein lactoferrin is present at mucosal surfaces and at sites of infection. Since lactoferrin is known to bind DNA, we tested the hypothesis that lactoferrin will bind CpG-containing ODN and modulate their biological activity. Physiological concentrations of lactoferrin (regardless of iron content) rapidly bound CpG ODN. The related iron-binding protein transferrin lacked this capacity. ODN binding by lactoferrin did not require the presence of CpG motifs and was calcium independent. The process was inhibited by high salt, and the highly cationic N-terminal sequence of lactoferrin (lactoferricin B) was equivalent to lactoferrin in its ODN-binding ability, suggesting that ODN binding by lactoferrin occurs via chargecharge interaction. Heparin and bacterial LPS, known to bind to the lactoferricin component of lactoferrin, also inhibited ODN binding. Lactoferrin and lactoferricin B, but not transferrin, inhibited CpG ODN stimulation of CD86 expression in the human Ramos B cell line and decreased cellular uptake of ODN, a process required for CpG bioactivity. Lactoferrin binding of CpG-containing ODN may serve to modulate and terminate host response to these potent immunostimulatory molecules at mucosal surfaces and sites of bacterial infection.",
author = "Britigan, {Bradley E} and Lewis, {T. S.} and M. Waldschmidt and McCormick, {M. L.} and Krieg, {A. M.}",
year = "2001",
month = "9",
day = "1",
doi = "10.4049/jimmunol.167.5.2921",
language = "English (US)",
volume = "167",
pages = "2921--2928",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells

AU - Britigan, Bradley E

AU - Lewis, T. S.

AU - Waldschmidt, M.

AU - McCormick, M. L.

AU - Krieg, A. M.

PY - 2001/9/1

Y1 - 2001/9/1

N2 - Unmethylated CpG dinucleotide motifs in bacterial DNA, as well as oligodeoxynucleotides (ODN) containing these motifs, are potent stimuli for many host immunological responses. These CpG motifs may enhance host responses to bacterial infection and are being examined as immune activators for therapeutic applications in cancer, allergy/asthma, and infectious diseases. However, little attention has been given to processes that down-modulate this response. The iron-binding protein lactoferrin is present at mucosal surfaces and at sites of infection. Since lactoferrin is known to bind DNA, we tested the hypothesis that lactoferrin will bind CpG-containing ODN and modulate their biological activity. Physiological concentrations of lactoferrin (regardless of iron content) rapidly bound CpG ODN. The related iron-binding protein transferrin lacked this capacity. ODN binding by lactoferrin did not require the presence of CpG motifs and was calcium independent. The process was inhibited by high salt, and the highly cationic N-terminal sequence of lactoferrin (lactoferricin B) was equivalent to lactoferrin in its ODN-binding ability, suggesting that ODN binding by lactoferrin occurs via chargecharge interaction. Heparin and bacterial LPS, known to bind to the lactoferricin component of lactoferrin, also inhibited ODN binding. Lactoferrin and lactoferricin B, but not transferrin, inhibited CpG ODN stimulation of CD86 expression in the human Ramos B cell line and decreased cellular uptake of ODN, a process required for CpG bioactivity. Lactoferrin binding of CpG-containing ODN may serve to modulate and terminate host response to these potent immunostimulatory molecules at mucosal surfaces and sites of bacterial infection.

AB - Unmethylated CpG dinucleotide motifs in bacterial DNA, as well as oligodeoxynucleotides (ODN) containing these motifs, are potent stimuli for many host immunological responses. These CpG motifs may enhance host responses to bacterial infection and are being examined as immune activators for therapeutic applications in cancer, allergy/asthma, and infectious diseases. However, little attention has been given to processes that down-modulate this response. The iron-binding protein lactoferrin is present at mucosal surfaces and at sites of infection. Since lactoferrin is known to bind DNA, we tested the hypothesis that lactoferrin will bind CpG-containing ODN and modulate their biological activity. Physiological concentrations of lactoferrin (regardless of iron content) rapidly bound CpG ODN. The related iron-binding protein transferrin lacked this capacity. ODN binding by lactoferrin did not require the presence of CpG motifs and was calcium independent. The process was inhibited by high salt, and the highly cationic N-terminal sequence of lactoferrin (lactoferricin B) was equivalent to lactoferrin in its ODN-binding ability, suggesting that ODN binding by lactoferrin occurs via chargecharge interaction. Heparin and bacterial LPS, known to bind to the lactoferricin component of lactoferrin, also inhibited ODN binding. Lactoferrin and lactoferricin B, but not transferrin, inhibited CpG ODN stimulation of CD86 expression in the human Ramos B cell line and decreased cellular uptake of ODN, a process required for CpG bioactivity. Lactoferrin binding of CpG-containing ODN may serve to modulate and terminate host response to these potent immunostimulatory molecules at mucosal surfaces and sites of bacterial infection.

UR - http://www.scopus.com/inward/record.url?scp=0035451425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035451425&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.167.5.2921

DO - 10.4049/jimmunol.167.5.2921

M3 - Article

VL - 167

SP - 2921

EP - 2928

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -